Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells
Grant Award Details
Grant Type:
Grant Number:
DISC2COVID19-12020
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$250,000
Status:
Closed
Grant Application Details
Application Title:
Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells
Public Abstract:
Research Objective
allogeneic HSC-engineered iNKT (HSC-iNKT) cells
Impact
treatment for COVID-19
Major Proposed Activities
allogeneic HSC-engineered iNKT (HSC-iNKT) cells
Impact
treatment for COVID-19
Major Proposed Activities
- Milestone 1. Production of AlloHSC-iNKT and UHSC-iNKT cells
- Milestone 2. Characterization of the AlloHSC-iNKT and UHSC-iNKT cells
- Milestone 3. Delivery of the new therapeutic candidate
Statement of Benefit to California:
The novel SARS-CoV-2 is the cause of the coronavirus disease 19 (COVID-19) pandemic, which is responsible for over 10.3 million cases and 500,000 deaths worldwide. There are over 2.6 million COVID-19 cases in the US, including over 217,000 cases in California. The proposed off-the-shelf allogeneic HSC-engineered iNKT (HSC-iNKT) cell therapy, if successful, may provide a treatment and save lives of COVID-19 patients at California.
Publications
- Cell Stem Cell (2023): Advancing cell-based cancer immunotherapy through stem cell engineering. (PubMed: 36948187)
- Stem Cell Res Ther (2022): Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. (PubMed: 35313965)